IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.21 Million USD | 42.12% |
| 2022 | 9.3 Million USD | 23.65% |
| 2021 | 7.52 Million USD | -13.65% |
| 2020 | 8.71 Million USD | 16.86% |
| 2019 | 7.45 Million USD | 555.58% |
| 2018 | 1.13 Million USD | -82.16% |
| 2017 | 6.37 Million USD | 139.82% |
| 2016 | 2.65 Million USD | 334.1% |
| 2015 | -1.13 Million USD | 74.2% |
| 2014 | -4.39 Million USD | 12.11% |
| 2013 | -5 Million USD | -143.08% |
| 2012 | -2.05 Million USD | 41.26% |
| 2011 | -3.5 Million USD | -206.38% |
| 2010 | -1.14 Million USD | 24.98% |
| 2009 | -1.52 Million USD | -733.11% |
| 2008 | 240.86 Thousand USD | 28.21% |
| 2007 | 187.86 Thousand USD | 639.62% |
| 2006 | -34.81 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 15.68 Million USD | 18.65% |
| 2023 Q2 | 13.7 Million USD | 17.92% |
| 2023 FY | 13.21 Million USD | 42.12% |
| 2023 Q4 | 13.21 Million USD | -3.02% |
| 2023 Q3 | 13.63 Million USD | -0.52% |
| 2023 Q1 | 11.62 Million USD | 24.93% |
| 2022 Q3 | 9.01 Million USD | 4.88% |
| 2022 Q4 | 9.3 Million USD | 3.23% |
| 2022 Q1 | 8.31 Million USD | 10.6% |
| 2022 Q2 | 8.59 Million USD | 3.27% |
| 2022 FY | 9.3 Million USD | 23.65% |
| 2021 Q2 | 5.13 Million USD | -46.58% |
| 2021 Q4 | 7.52 Million USD | 10.15% |
| 2021 FY | 7.52 Million USD | -13.65% |
| 2021 Q3 | 6.82 Million USD | 32.89% |
| 2021 Q1 | 9.62 Million USD | 10.44% |
| 2020 Q1 | 7.76 Million USD | 4.11% |
| 2020 Q2 | 7.97 Million USD | 2.76% |
| 2020 FY | 8.71 Million USD | 16.86% |
| 2020 Q3 | 7.93 Million USD | -0.48% |
| 2020 Q4 | 8.71 Million USD | 9.77% |
| 2019 FY | 7.45 Million USD | 555.58% |
| 2019 Q4 | 7.45 Million USD | 49.95% |
| 2019 Q3 | 4.97 Million USD | 51.0% |
| 2019 Q2 | 3.29 Million USD | 52.76% |
| 2019 Q1 | 2.15 Million USD | 89.53% |
| 2018 Q2 | 6.04 Million USD | -13.89% |
| 2018 Q3 | 6.75 Million USD | 11.76% |
| 2018 FY | 1.13 Million USD | -82.16% |
| 2018 Q4 | 1.13 Million USD | -83.17% |
| 2018 Q1 | 7.02 Million USD | 10.17% |
| 2017 Q1 | 2.82 Million USD | 6.13% |
| 2017 FY | 6.37 Million USD | 139.82% |
| 2017 Q4 | 6.37 Million USD | -1.89% |
| 2017 Q3 | 6.49 Million USD | 252.41% |
| 2017 Q2 | 1.84 Million USD | -34.65% |
| 2016 FY | 2.65 Million USD | 334.1% |
| 2016 Q4 | 2.65 Million USD | 597.38% |
| 2016 Q3 | 381 Thousand USD | -83.71% |
| 2016 Q2 | 2.33 Million USD | 982.87% |
| 2016 Q1 | 216 Thousand USD | 119.03% |
| 2015 Q1 | -3.42 Million USD | 22.16% |
| 2015 Q3 | -1.89 Million USD | 16.22% |
| 2015 FY | -1.13 Million USD | 74.2% |
| 2015 Q2 | -2.26 Million USD | 33.91% |
| 2015 Q4 | -1.13 Million USD | 40.14% |
| 2014 FY | -4.39 Million USD | 12.11% |
| 2014 Q3 | -4.37 Million USD | 15.49% |
| 2014 Q2 | -5.17 Million USD | -0.23% |
| 2014 Q1 | -5.16 Million USD | -3.22% |
| 2014 Q4 | -4.39 Million USD | -0.53% |
| 2013 Q1 | -2.16 Million USD | -5.29% |
| 2013 FY | -5 Million USD | -143.08% |
| 2013 Q4 | -5 Million USD | -96.2% |
| 2013 Q3 | -2.55 Million USD | -11.69% |
| 2013 Q2 | -2.28 Million USD | -5.35% |
| 2012 Q1 | -4.05 Million USD | -15.81% |
| 2012 FY | -2.05 Million USD | 41.26% |
| 2012 Q4 | -2.05 Million USD | 25.61% |
| 2012 Q3 | -2.76 Million USD | 9.39% |
| 2012 Q2 | -3.05 Million USD | 24.74% |
| 2011 Q1 | -575 Thousand USD | 49.74% |
| 2011 Q2 | -3.2 Million USD | -456.7% |
| 2011 Q3 | -3.32 Million USD | -3.72% |
| 2011 Q4 | -3.5 Million USD | -5.57% |
| 2011 FY | -3.5 Million USD | -206.38% |
| 2010 Q1 | -1.03 Million USD | 32.0% |
| 2010 FY | -1.14 Million USD | 24.98% |
| 2010 Q3 | -1.74 Million USD | -365.6% |
| 2010 Q2 | -375 Thousand USD | 63.84% |
| 2010 Q4 | -1.14 Million USD | 34.48% |
| 2009 Q3 | -2.1 Million USD | -304.05% |
| 2009 Q2 | 1.03 Million USD | 62.75% |
| 2009 Q4 | -1.52 Million USD | 27.52% |
| 2009 Q1 | 633.5 Thousand USD | 163.02% |
| 2009 FY | -1.52 Million USD | -733.11% |
| 2008 Q2 | -540.01 Thousand USD | 76.47% |
| 2008 Q4 | 240.86 Thousand USD | 425.7% |
| 2008 Q3 | -73.95 Thousand USD | 86.31% |
| 2008 Q1 | -2.29 Million USD | -1321.41% |
| 2008 FY | 240.86 Thousand USD | 28.21% |
| 2007 Q2 | -819.71 Thousand USD | -827.63% |
| 2007 Q4 | 187.86 Thousand USD | 134.58% |
| 2007 Q1 | 112.65 Thousand USD | 423.58% |
| 2007 FY | 187.86 Thousand USD | 639.62% |
| 2007 Q3 | -543.32 Thousand USD | 33.72% |
| 2006 Q2 | -416.81 Thousand USD | 0.0% |
| 2006 Q4 | -34.81 Thousand USD | 86.68% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | -34.81 Thousand USD | 0.0% |
| 2006 Q3 | -261.34 Thousand USD | 37.3% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HST Global, Inc. | 96.79 Thousand USD | -13556.979% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1981.185% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -7935.427% |
| CytoDyn Inc. | 20.26 Million USD | 34.76% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -2.109% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | 90.04 USD | -14681152.777% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -196.588% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -134.032% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -9355.38% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -6468.317% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 7292.526% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 69.565% |
| SQZ Biotechnologies Company | -36.23 Million USD | 136.478% |
| Resverlogix Corp. | 6.45 Million USD | -104.914% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -2023.998% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -491.234% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -454.016% |
| Mesoblast Limited | 55.85 Million USD | 76.335% |
| GB Sciences, Inc. | 1.74 Million USD | -656.532% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1981.185% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 69.109% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 249.538% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -3.22% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 2063.93% |
| ContraFect Corporation | -6.02 Million USD | 319.366% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -140.263% |
| BioStem Technologies, Inc. | 4.47 Million USD | -195.594% |
| LadRx Corporation | -2.03 Million USD | 749.114% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -66437.474% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -166.673% |
| CSL Limited | 10.52 Billion USD | 99.874% |
| Biomind Labs Inc. | 711.4 Thousand USD | -1758.162% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -988.98% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 309.675% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 5395.649% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 16.139% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -221.003% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 56.736% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -1325.712% |
| Marizyme, Inc. | 18.56 Million USD | 28.812% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1843.971% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -71.542% |
| Zenith Capital Corp. | 10.06 Thousand USD | -131249.364% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -489.546% |
| Halberd Corporation | 144.72 Thousand USD | -9034.127% |
| Genus plc | 190.6 Million USD | 93.065% |
| Pharming Group N.V. | 109.8 Million USD | 87.961% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -1436.662% |
| IMV Inc. | 7.67 Million USD | -72.335% |
| Affymax, Inc. | -5.59 Million USD | 336.18% |
| SYBLEU INC | 473.71 Thousand USD | -2690.502% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 128.118% |
| Enzolytics Inc. | 981.65 Thousand USD | -1246.602% |
| argenx SE | -2.02 Billion USD | 100.652% |
| AVAX Technologies, Inc. | -5.9 Million USD | 323.929% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -1044.077% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 1009183.969% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1901.008% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 2043222.102% |
| Cell Source, Inc. | 9.23 Million USD | -43.187% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -866.322% |
| Q BioMed Inc. | 4.06 Million USD | -225.59% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -9620.639% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 34.805% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1211.778% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -9718.106% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 78.167% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -561.151% |
| Rebus Holdings, Inc. | 305 Thousand USD | -4234.098% |
| Helix BioMedix, Inc. | -2.57 Million USD | 614.352% |
| Skye Bioscience, Inc. | -5.72 Million USD | 331.045% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -3574.905% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 72263.992% |
| ONE Bio Corp. | 9.04 Million USD | -46.227% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -500.323% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -6310.238% |
| Agentix Corp. | 37.63 Thousand USD | -35027.953% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -86.947% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -388.035% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -6495.254% |
| Kadimastem Ltd | -253.1 Thousand USD | 5322.796% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -3189.544% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 64873.618% |
| NovAccess Global Inc. | 2.17 Million USD | -506.803% |
| Itoco Inc. | 228.3 Thousand USD | -5690.062% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 142725.324% |
| Qrons Inc. | 351.42 Thousand USD | -3661.521% |
| Mobile Lads Corp. | 484.23 Thousand USD | -2629.89% |
| Genscript Biotech Corporation | -1.06 Billion USD | 101.246% |
| International Stem Cell Corporation | 2.59 Million USD | -410.386% |
| Bioxytran, Inc. | 1.89 Million USD | -596.135% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -21079.882% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -506.126% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -284.945% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -54.554% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -1610.96% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 1157.52% |
| Neutra Corp. | 52.18 Thousand USD | -25230.063% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 631.097% |
| PureTech Health plc | -167.19 Million USD | 107.906% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 5497.537% |
| IXICO plc | -4.44 Million USD | 397.418% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 75.9% |
| CSL Limited | 10.52 Billion USD | 99.874% |
| Cellectis S.A. | -43.81 Million USD | 130.167% |